JP2002534481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002534481A5 JP2002534481A5 JP2000593332A JP2000593332A JP2002534481A5 JP 2002534481 A5 JP2002534481 A5 JP 2002534481A5 JP 2000593332 A JP2000593332 A JP 2000593332A JP 2000593332 A JP2000593332 A JP 2000593332A JP 2002534481 A5 JP2002534481 A5 JP 2002534481A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- pharmaceutical composition
- seq
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH51/99 | 1999-01-13 | ||
| CH5199 | 1999-01-13 | ||
| PCT/EP2000/000174 WO2000041722A1 (de) | 1999-01-13 | 2000-01-12 | Verwendung von antikörpern zur vakzinierung gegen krebs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002534481A JP2002534481A (ja) | 2002-10-15 |
| JP2002534481A5 true JP2002534481A5 (enExample) | 2007-03-01 |
| JP4774551B2 JP4774551B2 (ja) | 2011-09-14 |
Family
ID=4178206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000593332A Expired - Fee Related JP4774551B2 (ja) | 1999-01-13 | 2000-01-12 | 抗癌ワクチン接種のための抗体の使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7691372B2 (enExample) |
| EP (2) | EP1230932B1 (enExample) |
| JP (1) | JP4774551B2 (enExample) |
| KR (1) | KR100771752B1 (enExample) |
| CN (1) | CN1188169C (enExample) |
| AT (2) | ATE286745T1 (enExample) |
| AU (1) | AU768515B2 (enExample) |
| CA (1) | CA2360382C (enExample) |
| CZ (1) | CZ302801B6 (enExample) |
| DE (2) | DE50000243D1 (enExample) |
| DK (2) | DK1230932T3 (enExample) |
| EE (1) | EE05474B1 (enExample) |
| ES (2) | ES2177509T3 (enExample) |
| HK (1) | HK1044487B (enExample) |
| HR (1) | HRP20010526A2 (enExample) |
| HU (1) | HU226150B1 (enExample) |
| ID (1) | ID30223A (enExample) |
| IL (2) | IL144265A0 (enExample) |
| IS (1) | IS5998A (enExample) |
| MX (1) | MXPA01007148A (enExample) |
| NO (1) | NO329917B1 (enExample) |
| NZ (1) | NZ512722A (enExample) |
| PL (1) | PL201533B1 (enExample) |
| PT (2) | PT1230932E (enExample) |
| SI (2) | SI1230932T1 (enExample) |
| SK (1) | SK286627B6 (enExample) |
| TR (1) | TR200102034T2 (enExample) |
| WO (1) | WO2000041722A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1230932B1 (de) * | 1999-01-13 | 2005-01-12 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verwendung von Antikörpern zur Vakzinierung gegen Krebs |
| AT410172B (de) * | 2000-03-21 | 2003-02-25 | Igeneon Gmbh | Verfahren zur herstellung einer vakzineformulierung |
| US20070122406A1 (en) | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
| AT502293B1 (de) * | 2002-05-15 | 2008-03-15 | Igeneon Krebs Immuntherapie | Immunogener, monoklonaler antikörper |
| AT500647A1 (de) * | 2002-05-21 | 2006-02-15 | Igeneon Krebs Immuntherapie | Verwendung eines impfstoffes |
| AT500650B1 (de) | 2003-04-17 | 2009-11-15 | Altropus Gmbh | Immunogener rekombinanter antikörper |
| AT500651B9 (de) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| WO2006005367A1 (en) | 2004-07-14 | 2006-01-19 | Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag | N-glycosylated antibody |
| EP1618890B1 (en) * | 2004-07-20 | 2010-10-06 | Altropus Gmbh | Use of antibodies in a very low dose for the vaccination against cancer |
| CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| AT504231A1 (de) | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| EP2217253B1 (en) | 2007-12-07 | 2011-06-29 | N.V. Nutricia | Bifidobacterium for dust mite allergy |
| MX2011007049A (es) | 2009-02-24 | 2011-08-03 | Esbatech Alcon Biomed Res Unit | Metodos para identificar inmunoligadores de los antegenos de la superficie celular. |
| US8887373B2 (en) | 2012-02-24 | 2014-11-18 | Covidien Lp | Vessel sealing instrument with reduced thermal spread and method of manufacture therefor |
| US20140276968A1 (en) * | 2013-03-14 | 2014-09-18 | Ethicon, Inc. | Applicator systems for surgical fasteners |
| US10196458B2 (en) * | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341281C (en) * | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| WO1997005597A1 (en) * | 1995-07-31 | 1997-02-13 | Litton Systems Canada Limited | Flat panel pixel array incorporating photoconductive switches |
| EP0857176A1 (en) * | 1995-10-25 | 1998-08-12 | Centocor B.V. | HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE |
| US6235280B1 (en) | 1996-04-12 | 2001-05-22 | Malaya Chatterjee | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 |
| IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
| US6274143B1 (en) * | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
| ATE480566T1 (de) * | 1998-06-15 | 2010-09-15 | Quest Pharmatech Inc | Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs |
| EP1230932B1 (de) * | 1999-01-13 | 2005-01-12 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verwendung von Antikörpern zur Vakzinierung gegen Krebs |
| AU2001261371A1 (en) | 2000-05-16 | 2001-11-26 | New York University | Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same |
-
2000
- 2000-01-12 EP EP02005394A patent/EP1230932B1/de not_active Expired - Lifetime
- 2000-01-12 WO PCT/EP2000/000174 patent/WO2000041722A1/de not_active Ceased
- 2000-01-12 HK HK02106215.4A patent/HK1044487B/zh not_active IP Right Cessation
- 2000-01-12 PT PT02005394T patent/PT1230932E/pt unknown
- 2000-01-12 CZ CZ20012581A patent/CZ302801B6/cs not_active IP Right Cessation
- 2000-01-12 DE DE50000243T patent/DE50000243D1/de not_active Expired - Lifetime
- 2000-01-12 PT PT00906191T patent/PT1140168E/pt unknown
- 2000-01-12 AU AU27964/00A patent/AU768515B2/en not_active Ceased
- 2000-01-12 ES ES00906191T patent/ES2177509T3/es not_active Expired - Lifetime
- 2000-01-12 HR HR20010526A patent/HRP20010526A2/hr not_active Application Discontinuation
- 2000-01-12 SI SI200030594T patent/SI1230932T1/xx unknown
- 2000-01-12 ID IDW00200101396A patent/ID30223A/id unknown
- 2000-01-12 CN CNB008027641A patent/CN1188169C/zh not_active Expired - Fee Related
- 2000-01-12 SI SI200030015T patent/SI1140168T1/xx unknown
- 2000-01-12 TR TR2001/02034T patent/TR200102034T2/xx unknown
- 2000-01-12 IL IL14426500A patent/IL144265A0/xx active IP Right Grant
- 2000-01-12 ES ES02005394T patent/ES2236375T3/es not_active Expired - Lifetime
- 2000-01-12 PL PL364747A patent/PL201533B1/pl not_active IP Right Cessation
- 2000-01-12 AT AT02005394T patent/ATE286745T1/de active
- 2000-01-12 NZ NZ512722A patent/NZ512722A/en not_active IP Right Cessation
- 2000-01-12 MX MXPA01007148A patent/MXPA01007148A/es not_active IP Right Cessation
- 2000-01-12 SK SK964-2001A patent/SK286627B6/sk not_active IP Right Cessation
- 2000-01-12 KR KR1020017008697A patent/KR100771752B1/ko not_active Expired - Fee Related
- 2000-01-12 CA CA2360382A patent/CA2360382C/en not_active Expired - Fee Related
- 2000-01-12 EE EEP200100366A patent/EE05474B1/xx not_active IP Right Cessation
- 2000-01-12 DK DK02005394T patent/DK1230932T3/da active
- 2000-01-12 JP JP2000593332A patent/JP4774551B2/ja not_active Expired - Fee Related
- 2000-01-12 HU HU0200527A patent/HU226150B1/hu not_active IP Right Cessation
- 2000-01-12 DE DE50009240T patent/DE50009240D1/de not_active Expired - Lifetime
- 2000-01-12 AT AT00906191T patent/ATE219687T1/de active
- 2000-01-12 EP EP00906191A patent/EP1140168B1/de not_active Expired - Lifetime
- 2000-01-12 DK DK00906191T patent/DK1140168T3/da active
-
2001
- 2001-06-21 NO NO20013093A patent/NO329917B1/no not_active IP Right Cessation
- 2001-07-10 IS IS5998A patent/IS5998A/is unknown
- 2001-07-11 IL IL144265A patent/IL144265A/en not_active IP Right Cessation
-
2006
- 2006-10-10 US US11/548,269 patent/US7691372B2/en not_active Expired - Fee Related
-
2009
- 2009-09-18 US US12/562,886 patent/US20100233178A1/en not_active Abandoned
-
2011
- 2011-08-12 US US13/209,285 patent/US8444974B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002534481A5 (enExample) | ||
| CA2170236C (en) | Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes | |
| Hopp | Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier | |
| CA2321161A1 (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| CA2371714A1 (en) | Streptococcus pneumoniae proteins and vaccines | |
| WO2000020027A3 (en) | Methods for therapeutic vaccination | |
| JP2003505431A5 (enExample) | ||
| CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
| JP2002512026A5 (enExample) | ||
| CA2360382A1 (en) | Use of antibodies for the vaccination against cancer | |
| RU2012149618A (ru) | Менингококковые полипептиды fhbp | |
| JP2006506441A5 (enExample) | ||
| US6641816B1 (en) | Use of poxviruses as enhancer of specific immunity | |
| WO2002032923A3 (en) | Improved formulations using heat shock/stress protein-peptide complexes | |
| AU707083B2 (en) | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes | |
| EP0714307B1 (en) | Vaccine compositions | |
| CA2337754A1 (en) | Recombinant multivalent malarial vaccine against plasmodium falciparum | |
| ES2551699T3 (es) | Composiciones, procedimientos y kits | |
| Chen et al. | Extract from Agaricus blazei Murill can enhance immune responses elicited by DNA vaccine against foot-and-mouth disease | |
| CA2295971A1 (en) | Pseudomonas exotoxin a-like chimeric immunogens | |
| Yi et al. | Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65 | |
| JPWO2021236980A5 (enExample) | ||
| WO2003078595B1 (en) | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response | |
| CN1056816A (zh) | 改良的疫苗组合物 | |
| RU98112608A (ru) | Иммуногенная композиция [на основе] tlp |